GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Pediatrix Medical Group Inc (NYSE:MD) » Definitions » ROE %
中文

Pediatrix Medical Group (Pediatrix Medical Group) ROE % : -54.72% (As of Dec. 2023)


View and export this data going back to 1959. Start your Free Trial

What is Pediatrix Medical Group ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Pediatrix Medical Group's annualized net income for the quarter that ended in Dec. 2023 was $-497 Mil. Pediatrix Medical Group's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $909 Mil. Therefore, Pediatrix Medical Group's annualized ROE % for the quarter that ended in Dec. 2023 was -54.72%.

The historical rank and industry rank for Pediatrix Medical Group's ROE % or its related term are showing as below:

MD' s ROE % Range Over the Past 10 Years
Min: -70.91   Med: 9.87   Max: 15.93
Current: -6.62

During the past 13 years, Pediatrix Medical Group's highest ROE % was 15.93%. The lowest was -70.91%. And the median was 9.87%.

MD's ROE % is ranked worse than
69.51% of 610 companies
in the Healthcare Providers & Services industry
Industry Median: 4.115 vs MD: -6.62

Pediatrix Medical Group ROE % Historical Data

The historical data trend for Pediatrix Medical Group's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pediatrix Medical Group ROE % Chart

Pediatrix Medical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -65.30 -70.91 15.93 7.42 -6.94

Pediatrix Medical Group Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.56 6.31 12.22 8.96 -54.72

Competitive Comparison of Pediatrix Medical Group's ROE %

For the Medical Care Facilities subindustry, Pediatrix Medical Group's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pediatrix Medical Group's ROE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Pediatrix Medical Group's ROE % distribution charts can be found below:

* The bar in red indicates where Pediatrix Medical Group's ROE % falls into.



Pediatrix Medical Group ROE % Calculation

Pediatrix Medical Group's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-60.408/( (891.632+849.061)/ 2 )
=-60.408/870.3465
=-6.94 %

Pediatrix Medical Group's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-497.148/( (967.985+849.061)/ 2 )
=-497.148/908.523
=-54.72 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Pediatrix Medical Group  (NYSE:MD) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-497.148/908.523
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-497.148 / 1985.772)*(1985.772 / 2273.0745)*(2273.0745 / 908.523)
=Net Margin %*Asset Turnover*Equity Multiplier
=-25.04 %*0.8736*2.5019
=ROA %*Equity Multiplier
=-21.87 %*2.5019
=-54.72 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-497.148/908.523
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-497.148 / -555.4) * (-555.4 / 156.164) * (156.164 / 1985.772) * (1985.772 / 2273.0745) * (2273.0745 / 908.523)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.8951 * -3.5565 * 7.86 % * 0.8736 * 2.5019
=-54.72 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Pediatrix Medical Group ROE % Related Terms

Thank you for viewing the detailed overview of Pediatrix Medical Group's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Pediatrix Medical Group (Pediatrix Medical Group) Business Description

Traded in Other Exchanges
Address
1301 Concord Terrace, Sunrise, FL, USA, 33323
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment, which is physician services. The company generates roughly half of its revenue from the women's and children's services provided, and also roughly half of the company's total revenue is earned in the United States.
Executives
James D Swift officer: EVP, Chief Operating Officer 1301 CONCORD TERRACE, SUNRISE FL 33323
Moore Mary Ann E officer: EVP Chief ERM/Legal Ops Off 1301 CONCORD TERRACE, SUNRISE FL 33323
Mark S Ordan director, officer: Chief Executive Officer 7315 WISCONSIN AVENUE, SUITE #250 WEST, BETHESDA MD 20814
Shirley A Weis director 11621 RESEARCH CIRCLE, GAINESVILLE FL 32615
Sylvia Jean Young director C/O LINCOLN EDUCATIONAL SERVICES CORPORA, 14 SYLVAN WAY, STE. A, PARSIPPANY NJ 07054
Lee Wood officer: EVP, Natl & Market Operations 1301 CONCORD TERRACE, SUNRISE FL 33323
Curtis Pickert officer: EVP, Chief Operating Officer 1301 CONCORD TERRACE, SUNRISE FL 33323
Laura A Linynsky director 1301 CONCORD TERRACE, SUNRISE FL 33323
Roger Md Medel director, officer: PRES. & CHIEF EXEC. OFFICER 1301 CONCORD TERRACE, SUNRISE FL 33323
John C Pepia officer: Principal Accounting Officer 1301 CONCORD TERRACE, SUNRISE FL 33323
Roger Mack Hinson officer: Pres., PDX & OBX Medical Group C/O MEDNAX, INC., 1301 CONCORD TERRACE, SUNRISE FL 33323
C Marc Richards officer: EVP, Chief Financial Officer 7315 WISCONSIN AVENUE, SUITE 250-W, BETHESDA MD 20814
Dominic J Andreano officer: Sr.VP,General Counsel & Secy. 1301 CONCORD TERRACE, SUNRISE FL 33323
Nicholas Nikolopoulos officer: EVP Chf Strategy & Growth Offi MEDNAX INC, 1301, SUNRISE FL 33323
Guy P Sansone director C/O MEDNAX, 1301 CONCORD TERRACE, SUNRISE FL 33323